Drugs / NivobotulinumtoxinA
NivobotulinumtoxinA
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT01588574 | Aug 2012 → Oct 2013 | cervical dystonia | Medy-Tox | Completed | No outcome recorded |
| Phase 2 | NCT01485601 | Dec 2011 → Mar 2012 | — | Medy-Tox | Completed | No outcome recorded |
| Phase 35 trials | ||||||
| Phase 3 | NCT04157686 | Oct 2019 → Feb 2023 | — | Medy-Tox | Completed | No outcome recorded |
| Phase 3 | NCT03795922 | Dec 2018 → Mar 2020 | — | Medy-Tox | Completed | No outcome recorded |
| Phase 3 | NCT03785145 | Dec 2018 → Feb 2020 | eyelid disorder | Medy-Tox | Completed | No outcome recorded |
| Phase 3 | NCT03732833 | Nov 2018 → Mar 2020 | eyelid disorder | Medy-Tox | Completed | No outcome recorded |
| Phase 3 | NCT03721016 | Oct 2018 → Mar 2020 | — | Medy-Tox | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NivobotulinumtoxinA | “MT10109L (NivobotulinumtoxinA)” NCT04157686 ↗ |
| Known as | MT10109 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01588574 ↗ |
| Known as | MT10109-DS | ChEMBL registry synonym — accepted as the source's own label CHEMBL3990013 ↗ |
| Known as | MT10109L | “MT10109L (NivobotulinumtoxinA)” NCT04157686 ↗ |
| Modality | Protein / enzyme biologic | “Biological: MT10109” NCT01485601 ↗ |
| Route | Intramuscular | “administered by intramuscular injection” NCT01485601 ↗ |